Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Marche-en-Famenne – page 28

797 clinical trials in Marche-en-Famenne, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Marche-en-Famenne at a glance
797
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

797 trials in Marche-en-Famenne

Open in trial search

Crohn's disease

Not yet recruiting

Clinical trial of subcutaneous infliximab in patients with perianal fistulizing Crohn’s disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:CHU De Liege

Narcolepsy

Not yet recruiting

A Randomized, Double‑Blind Study of ORX750 versus Placebo for Excessive Daytime Sleepiness in Adults with Narcolepsy (Type 1 and Type 2)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ORX750
  • Sponsor:Centessa Pharmaceuticals UK Limited

Bronchitis+1

Not yet recruiting

Study of galvokimig versus placebo to assess safety and effectiveness in adults with moderate‑to‑severe chronic obstructive pulmonary disease with chronic bronchitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Galvokimig
  • Sponsor:UCB Biopharma

Phase 2 Study of Weekly Ficerafusp Alfa + Pembrolizumab vs Alternative Dosing in First‑Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ficerafusp alfa
  • Sponsor:Bicara Therapeutics Inc.

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Secondary immunodeficiency

Not yet recruiting

Study of Human Normal Immunoglobulin in Adults with Secondary Immune Deficiency after CAR T‑cell or T‑cell Redirecting Therapy for Hematologic Malignancies

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:CSL Behring LLC

Thrombosis prophylaxis

Not yet recruiting

Randomized trial of standard vs high-dose enoxaparin and sodium chloride for preventing clots in critically ill ICU patients at high risk of thrombosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Hopital Erasme

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Glaxosmithkline Research & Development Limited

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of epcoritamab, venetoclax and ibrutinib in treatment‑naïve chronic lymphocytic leukemia patients with TP53 alterations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:LYSARC

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Marche-en-Famenne

What the registry says about research in the country

01 Infectious Disease Research

Clinical investigations focusing on Epstein-Barr Virus (EBV) infections and their associated symptoms, particularly examining therapeutic approaches for virus-related fatigue and asthenia.

  • Viral Infection Management
  • Fatigue Treatment Assessment
  • Symptom Control Studies

These controlled trials evaluate novel therapeutic options for managing EBV-related conditions, with particular attention to improving patient quality of life through fatigue reduction strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.